pazopanib 200 MG Oral Tablet [Votrient]
pazopanib
RxCUI: 867506
What the CMS Formulary Data Shows for pazopanib 200 MG Oral Tablet [Votrient]
Per the CMS 2026 Part D formulary file, pazopanib 200 MG Oral Tablet [Votrient] (RxNorm concept RXCUI 867506, generic name pazopanib) appears on 4 distinct formulary files spanning 19 Medicare Part D plan offerings - 0.4% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.
Real-world access to pazopanib 200 MG Oral Tablet [Votrient] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 50% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,555 Part D beneficiaries filled pazopanib 200 MG Oral Tablet [Votrient] in 2023, with total plan-and-beneficiary spending of $97,957,715 and an average per-beneficiary annual cost of $62,995.32. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry pazopanib 200 MG Oral Tablet [Votrient] today.
Coverage Details
- Formularies covering
- 4
- Plans covering
- 19
- Coverage rate
- 0.4%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 50% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,555
- Total spending
- $97,957,715
- Avg per beneficiary
- $62,995.32
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering pazopanib 200 MG Oral Tablet [Votrient]
19 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | Yes | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | Yes | $34.50 | NY |
| MCS Classicare RxMax (HMO) | MCS ADVANTAGE, INC. | T5 | Yes | $0 | PR |
| Health First Rewards H1099-014 (HMO) | HEALTH FIRST HEALTH PLANS | T5 | Yes | $0 | FL |
| Health First SunSaver H1099-016 (HMO) | HEALTH FIRST HEALTH PLANS | T5 | Yes | $0 | FL |
| Health First Complete Care H1099-023 (HMO) | HEALTH FIRST HEALTH PLANS | T5 | Yes | $0 | FL |
| Health First Emerald Plus H1099-024 (HMO) | HEALTH FIRST HEALTH PLANS | T5 | Yes | $0 | FL |
| Health First Premier Access H1099-025 (HMO-POS) | HEALTH FIRST HEALTH PLANS | T5 | Yes | $0 | FL |
| Health First Emerald Plus H1099-026 (HMO) | HEALTH FIRST HEALTH PLANS | T5 | Yes | $0 | FL |
| Health First Premier Access H1099-027 (HMO-POS) | HEALTH FIRST HEALTH PLANS | T5 | Yes | $0 | FL |
| Health First Emerald Plus H1099-028 (HMO) | HEALTH FIRST HEALTH PLANS | T5 | Yes | $0 | FL |
| Health First Value H1099-006 (HMO) | HEALTH FIRST HEALTH PLANS | T5 | Yes | $15.00 | FL |
| Keystone 65 Select Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T5 | Yes | $47.00 | PA |
| Health First Classic H1099-001 (HMO-POS) | HEALTH FIRST HEALTH PLANS | T5 | Yes | $49.40 | FL |
| Keystone 65 Preferred Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T5 | Yes | $59.70 | PA |
| Keystone 65 Select Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T5 | Yes | $63.50 | PA |
| Keystone 65 Preferred Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T5 | Yes | $79.70 | PA |
| Personal Choice 65 Rx (PPO) | QCC INSURANCE COMPANY | T5 | Yes | $102.20 | PA |
| Personal Choice 65 Rx (PPO) | QCC INSURANCE COMPANY | T5 | Yes | $112.70 | PA |
Frequently Asked Questions
Is pazopanib 200 MG Oral Tablet [Votrient] covered by Medicare Part D?
Yes, pazopanib 200 MG Oral Tablet [Votrient] is covered by 19 Medicare Part D plans (0.4% of all Part D formularies).
What tier is pazopanib 200 MG Oral Tablet [Votrient] on Medicare Part D plans?
pazopanib 200 MG Oral Tablet [Votrient] averages Tier 4 across Part D plans, ranging from Tier 1 to Tier 5.
Does pazopanib 200 MG Oral Tablet [Votrient] require prior authorization?
100% of Part D formularies require prior authorization for pazopanib 200 MG Oral Tablet [Votrient]. Step therapy: 0%. Quantity limits: 50%.
How much does Medicare spend on pazopanib 200 MG Oral Tablet [Votrient]?
In 2023, total Medicare Part D spending on pazopanib 200 MG Oral Tablet [Votrient] was $97,957,715, covering 1,555 beneficiaries. The average spend per beneficiary was $62,995.32.
Read our methodology - how this data is sourced, computed, and verified.